pbnewby, good news story and summary - imo all too common
''Novogen Anti-Tropomyosin Program Director, Justine Stehn PhD, said, “We are pleasantly surprised by the degree of anti-tumor activity of this drug candidate on its own. We had always seen the anti-tropomyosin technology as being an adjunct therapy for the more commonly used anti-mitotic drugs. The rationale behind its development was to destroy that half of a cancer cell’s cytoskeleton that the anti-mitotic drugs didn’t target. We reasoned that destabilising the entire cytoskeleton would achieve a much higher level of anti-cancer effect than that coming from targeting either half alone. And, indeed, that is what we see. Anisina used in combination with anti-mitotic drug, vincristine, increases the anti-cancer potency of vincristine 20-fold.”
- Forums
- ASX - By Stock
- KZA
- Ann: GDC 0084 progress update
Ann: GDC 0084 progress update, page-10
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)